Heritage Cannabis Holdings Corp. (CSE:CANN;OTC:HERTF) CEO Clint Sharples was featured in an interview with Midas Letter Live regarding its deal with EndoCanna Health Inc. and its partnership with CannTab Therapeutics Ltd. (CSE:PILL). Sharples gave a quick overview of what the company had been doing since he was last on the show which included signing partners, setting up an extraction business and making deals.

In May 2019, Heritage acquired a 30 percent interest in EndoCanna, a technology and DNA-based cannabis information service provider in the US. EndoCanna has developed a DNA swab kit, similar to those that 23andME and Ancestry provide. EndoCanna’s algorithm processes the information collected in the kit before presenting the user with a personalized report. The report outlines which cannabinoids would be best for that individual’s body and needs.

Sharples also talked about Heritage’s partnership with CannTab. Heritage’s subsidiary, Purefarma Solutions, will be providing hemp processing services for CannTab and Heritage will be assisting CannTab with packaging and distribution as the company rolls out its ingestible oral cannabis line.

He also discussed Heritage’s plans decision to exercise its option to acquire the CannaCure facility in Fort Erie, Ontario.

“Yeah, not just growing; the facility is 122,000 square feet. Twenty-four thousand square feet of that is for grow, and that grow will be very specific strains for our formulations that we want to put to market. So it’s, we’re not just talking about planting Light Widow or Purple Kush or any of the general recreational-based strains. This is designed to be very particular strains which have the various cannabinoids, which in our, mostly in our medical side, or quite possibly in the vape pen side, will show the best in the way of the formulated products,” said Sharples.

To watch the full interview, click here.

Click here to connect with Heritage Cannabis Holdings Corp. (CSE:CANN;OTC:HERTF) for an Investor Presentation. 

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less